Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Masato Takahashi, Eriko Tokunaga, Joji Mori, Yoshinori Tanizawa, Jan Stefan van der Walt, Tsutomu Kawaguchi, Matthew P. Goetz, Masakazu Toi
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer'. Together they form a unique fingerprint.